Core Insights - The rapid development of precision medicine and continuous humanistic care are providing hope for families facing the severe challenge of pediatric hematological tumors [1] - Beijing Borin Hospital's Pediatric Hematology and Oncology Department, led by Professor Zhang Yonghong, integrates cutting-edge diagnostic and treatment technologies with a holistic care philosophy, achieving breakthroughs in treating difficult cases and advancing China's pediatric hematological oncology system [1][4] Group 1: Case Study of a Pediatric Patient - A 7-year-old boy, Xiao Le, diagnosed with high-risk T-cell lymphoblastic lymphoma/leukemia, faced treatment challenges after multiple rounds of standard chemotherapy [2][3] - After a remote consultation with Professor Zhang, Xiao Le was transferred to Beijing Borin Hospital for comprehensive evaluation and targeted treatment, leading to the identification of a rare NRAS gene mutation as the core issue [3][4] - A personalized treatment plan was developed, incorporating targeted therapies and chemotherapy, resulting in effective disease control and successful stem cell transplantation [3][4] Group 2: Clinical Achievements and Innovations - The Pediatric Hematology and Oncology Department has become a national benchmark center for pediatric lymphoma treatment, achieving a cure rate increase from below 50% to over 90% in high-level centers through precision treatment [7] - The department has treated over 500 cases of difficult-to-treat relapsed lymphomas, achieving an overall remission rate exceeding 80% and a long-term progression-free survival rate of around 70% [8] - The team is innovating treatment paradigms by integrating targeted therapies and immunotherapies, significantly improving outcomes for patients with relapsed T-cell lymphoblastic lymphoma [11][12] Group 3: Research and International Collaboration - The department emphasizes a "clinical problem-driven research" approach, leading to significant contributions in molecular profiling and treatment target exploration, with multiple publications in prestigious journals [16][17] - The team has actively participated in international conferences, showcasing their research and gaining recognition for their contributions to pediatric lymphoma treatment [17] - The collaboration with the National Children's Lymphoma Collaborative Group (CNCL) has standardized treatment protocols across 46 major pediatric oncology centers in China, enhancing overall treatment outcomes [7][8] Group 4: Humanistic Care and Support - The department prioritizes humanistic care, ensuring that treatment extends beyond the disease to support the emotional and psychological needs of patients and their families [21] - Initiatives such as educational workshops for parents and community support events foster open communication and emotional support among families [21] - This combination of advanced medical techniques and compassionate care has significantly enhanced patients' confidence and resilience in battling their illnesses [21] Group 5: Future Directions - The department aims to continue advancing precision medicine and expanding treatment boundaries while maintaining a focus on humanistic care for pediatric patients [23] - Ongoing efforts will be made to integrate new treatment modalities and enhance the overall quality of life for children undergoing treatment [23]